Silence Therapeutics (SLN) Non-Current Deffered Revenue (2019 - 2026)

Silence Therapeutics (SLN) has 8 years of Non-Current Deffered Revenue data on file, last reported at $55.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 3.62% year-over-year to $55.2 million; the trailing twelve-month figure through Mar 2026 stood at $55.2 million (up 3.62% YoY), and the FY2025 full-year result was $55.5 million, up 7.07% from the prior year.
• Non-Current Deffered Revenue held at $55.2 million in Q1 2026, from $55.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $74.5 million in Q4 2022 to a low of $51.8 million in Q4 2024.
• A 5-year average of $59.4 million and a median of $55.4 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue dropped 29.17% in 2024 and gained 7.07% in 2025, its largest moves.
• Tracing SLN's Non-Current Deffered Revenue over 5 years: stood at $74.5 million in 2022, then retreated by 1.81% to $73.1 million in 2023, then retreated by 29.17% to $51.8 million in 2024, then grew by 7.07% to $55.5 million in 2025, then slipped by 0.43% to $55.2 million in 2026.
• Business Quant data shows SLN's Non-Current Deffered Revenue at $55.2 million in Q1 2026, $55.5 million in Q4 2025, and $55.3 million in Q3 2025.